11 articles with Synthon
4/23/2020Biopharma and life sciences groups from across the globe provide updates on their business and pipelines.
Synthon Biopharmaceuticals B.V., a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless cancers and autoimmune diseases, announced that it is relaunching as Byondis.
Guiding chemotherapy to a tumour by attaching it to the antibody-based target drug Herceptin is effective at treating women with breast cancer who have no other treatment options, a new clinical trial shows.
Synthon’s [vic-]Trastuzumab Duocarmazine (SYD985) Granted FDA Fast Track Designation For Pre-Treated HER2-Positive Metastatic Breast Cancer
This designation is for treating patients diagnosed with HER2-positive metastatic breast cancer (MBC) that has progressed during or after at least two HER2-targeting treatment regimens for locally advanced or metastatic disease, or progressed during or after [ado-]trastuzumab emtansine treatment.
Mylan, In Partnership With Synthon, Receives Marketing Authorization Approval In Europe For First Generic For Copaxone 40 Mg/Ml
Patents Licensed To Synthon Relating To The CD47-SIRPa Pathway Resist Challenges In The U.S. And Europe
Synthon Enters Worldwide Exclusive License And Collaboration With Sanquin For Immuno-Oncology Therapeutic Leads Modulating The CD47-Sirpa Pathway
Synthon Advances Clinical Evaluation Of Anti-HER2 ADC SYD985 In An Expanded Cohort Of HER2-Positive Metastatic Breast Cancer Patients